Eprosartan
Spécifications
133040-01-4Numéro CAS
4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acidNom IUPAC
C23H24N2O4SFormule chimique
424.5 g/molMasse molaire
Eprosartan; 133040-01-4; SK&F 108566; SK&F-108566; SKF-108566; (E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid; 2KH13Z0S0Y; SK-108566; CHEBI:4814; DTXSID0022989; (E)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid; (E)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid; 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4-carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)-; 4-[[2-butyl-5-[(E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; 4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; Eprosartanum; (E)-3-(2-n-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazol-5-yl)-2-(2-thienyl)methyl-2-propenoic acid; (E)-alpha((2-butyl-1-((4-carboxyphenyl)methyl)-1H-imidazole-5-yl)methylene)-2-thiopheneproprionic acid; 4-((2-butyl-5-((1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; 4-((2-butyl-5-((E)-3-hydroxy-3-oxo-2-(thiophen-2-ylmethyl)prop-1-enyl)imidazol-1-yl)methyl)benzoic acid; RefChem:590997; DTXCID002989; C09CA02; (E)-4-((2-Butyl-5-(2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl)-1H-imidazol-1-yl)methyl)benzoic acid; CHEMBL813; 4-[[2-butyl-5-[(E)-2-carboxy-3-thiophen-2-ylprop-1-enyl]imidazol-1-yl]methyl]benzoic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; 4-({2-butyl-5-[(1E)-2-carboxy-3-(thiophen-2-yl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; [3H]eprosartan; [3H]-eprosartan; Teveten; SK&F108566; NCGC00164557-01; Eprosartan (USAN/INN); UNII-2KH13Z0S0Y; Eprozar; Eprosartan [USAN:INN:BAN]; SR-05000001450; HSDB 7521; Eprosartan (Standard); [3H]SK&F 108566; EPROSARTAN [MI]; EPROSARTAN [INN]; EPROSARTAN [HSDB]; EPROSARTAN [USAN]; EPROSARTAN [VANDF]; SCHEMBL4025; EPROSARTAN [WHO-DD]; GTPL588; BIDD:GT0030; GTPL3940; orb1702349; CHEBI:94094; 4-[[2-butyl-5-(2-carboxy-3-thiophen-2-ylprop-1-enyl)-1-imidazolyl]methyl]benzoic acid; GLXC-08125; HMS2089O10; MSK10510; BDBM50011977; EBC-27048; MFCD20923872; STK618317; T2531L; AKOS005552473; DB00876; FE22770; HY-117743R; 4-[[2-butyl-5-[(E)-2-carboxy-3-(2-thienyl)prop-1-enyl]imidazol-1-yl]methyl]benzoic acid; NCGC00164557-06; NCGC00164557-11; NCGC00164557-13; (E)-3-[2-Butyl-1-[(4-carboxyphenyl)methyl]imidazol-5-yl]-2-(2-thienylmethyl)-2-propenoic acid; 4-({2-butyl-5-[(1E)-2-carboxy-2-[(thiophen-2-yl)methyl]eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid; BS-20679; HY-117743; CS-0067582; NS00000388; C07467; D04040; H11955; AB01275448-01; AB01275448_02; EN300-7397751; L000248; Q784717; SR-05000001450-1; BRD-K67977190-066-01-5; BRD-K67977190-066-02-3; BRD-K67977190-066-03-1; (E)-2-BUTYL-1-(P-CARBOXYBENZYL)-.ALPHA.-2-THENYLIMIDAZOLE-5-ACRYLIC ACID; (E)-3-[2-Butyl-1-[(4-carboxyphenyl)methyl]-imidazol-5-yl]-2-(2-thienyl methyl)-2-propenoic acid; (E)-alpha-[[2-Butyl-1-[(4-carboxyphenyl)-methyl]-1H-imidazol-5-yl]methylene]-2-thiophene Propanoic Acid; (E)-alpha-[[2-butyl-1-[(4carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-2-thiophene propanoic acid; 2-THIOPHENEPROPANOIC ACID, .ALPHA.-((2-BUTYL-1-((4-CARBOXYPHENYL)METHYL)-LH-IMIDAZOL-5-YL)METHYLENE)-, (E)-; 2-Thiophenepropanoic acid, |A-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-, (|AE)-Synonymes
